Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL
A phase III trial of idelalisib plus rituximab in patients with previously treated chronic lymphocytic leukemia found that the combo improved progression-free and overall survival, according to results presented at the 2013 ASH meeting.